







PREGLED NAJZNAČAJNIJIH NAUČNOISTRAŽIVAČKIH PROJEKATA I DRUGIH NAJZNAČAJNIJIH NAUČNIH DOSTIGNUĆA FARMACEUTSKOG FAKULTETA u PERIODU 2019-2024. (Fakultet nosilac projekta)

1.	2019: Horizon 2020-IMI project: NeuroDeRisk, From 2019-03-01 to 2022-09-30; EUR 9 752 062,50 (https://neuroderisk.eu/)	
2.	2020-2022: Fond za nauku RS/Science Fund of the RS; program PROMIS: PsyCise; EUR 199 872,88	
3.	2020-2022: Fond za nauku RS/Science Fund of the RS; program PROMIS: DecodExpo; EUR 186 522,28	
4.	2021: Horizon 2020-project PSY-PGx, From 2021-03-01 to 2026-02-28; EUR 7 999 611,75 (https://www.psy-pgx.org/PSY-PGx)	
5.	2021-2024: Strateški naučno-istraživački i razvojni projekat međunarodne saradnje između Republike Srbije i Narodne Republike Kine (451-03-1203/2021-09, Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije); USD 400.000	
6.	2022-2024: Fond za nauku RS/Science Fund of the RS; program IDEJE: HI-MOM; EUR 276 000,00	
7.	2022-2024: Fond za nauku RS/Science Fund of the RS; program IDEJE: Fight_PainAndComorb; EUR 165 507,45	
8.	2022-2024: Fond za nauku RS/Science Fund of the RS; program IDEJE: NanoCellEmoCog; EUR 276 000,00	
9.	2022-2024: Fond za nauku RS/Science Fund of the RS; program IDEJE: PhAgroWaste; EUR 275 442,85	

10.	2022-2024: Fond za nauku RS/Science Fund of the RS; program IDEJE: InfCanPlay; EUR 284 759,87	
11.	2022: Horizon Europe: CardioSCOPE; From 2023-01-01 to 2026-12-31; EUR 1 518 000,00	
12.	2024-2026: Fond za nauku RS/Science Fund of the RS; program PRIZMA: optYmAb; EUR 289 389.39	
13.	2024-2026: Fond za nauku RS/Science Fund of the RS; program PRIZMA: BioCompWaterClean; EUR 284 998.92	
14.	2024-2026: Fond za nauku RS/Science Fund of the RS; program PROMIS 2023: CoD-GOAT; EUR 140 000,00	

MEĐUNARODNI PATENTI / INTERNATIONAL PATENTS

1) 2020 - Primena modulatora selektivnih za GABAA receptore koji sadrže alfa6 podjedinicu: patent priznat na međunarodnom nivou. Koinventor: Miroslav Savić



(11) **EP 3 325 479 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
02.12.2020 Bulletin 2020/49

(21) Application number: **16804541.7**

(22) Date of filing: **03.06.2016**

(51) Int Cl.:
C07D 471/04 ^(2006.01) *C07D 471/14* ^(2006.01)
C07D 491/147 ^(2006.01) *C07D 495/14* ^(2006.01)
C07D 498/14 ^(2006.01) *A61K 31/437* ^(2006.01)
A61K 31/4375 ^(2006.01) *A61K 31/4439* ^(2006.01)
A61P 25/24 ^(2006.01) *A61P 25/06* ^(2006.01)
A61P 25/18 ^(2006.01) *A61P 27/16* ^(2006.01)

(86) International application number:
PCT/US2016/035761

(87) International publication number:
WO 2016/196961 (08.12.2016 Gazette 2016/49)

(54) **LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE**

(43) Date of publication of application:
30.05.2018 Bulletin 2018/22

(73) Proprietors:

- UWM Research Foundation, Inc.
Milwaukee, WI 53202 (US)
- Medical University Of Vienna
1090 Vienna (AT)
- National Taiwan University
Taipei 10617 (TW)
- University of Belgrade-Faculty of Pharmacy
Belgrade 11221 (RS)

(72) Inventors:

- CHIOU, Lih-Chu
Taipei 100 (TW)
- COOK, James
Milwaukee, WI 53217 (US)
- ERNST, Margot
1090 Vienna (AT)

- SIEGHART, Werner
1190 Vienna (AT)
- VARAGIC, Zdravko
1020 Vienna (AT)
- VERMA, Ranjit
Shorewood, WI 53211 (US)
- WIMMER, Laurin
5110 Oberndorf (AT)
- WITZIGMANN, Christopher
New Berlin, WI 53151 (US)
- SIEBERT, David, Chan Bodin
1070 Vienna (AT)
- SAVIC, Miroslav, M.
Belgrade 11000 (RS)

(74) Representative: **Stafford, Jonathan Alan Lewis
Marks & Clerk LLP
1 New York Street
Manchester M1 4HD (GB)**

**2) 2021 - Primena modulatora selektivnih za GABAA receptore koji sadrže alfa5
podjedinicu: patent priznat na međunarodnom nivou. Koinventor: Miroslav Savić**



US010906909B2

(12) **United States Patent**
Cook et al.

(10) **Patent No.: US 10,906,909 B2**
(45) **Date of Patent: Feb. 2, 2021**

(54) **TREATMENT OF COGNITIVE AND MOOD
SYMPTOMS IN NEURODEGENERATIVE
AND NEUROPSYCHIATRIC DISORDERS
WITH ALPHA5-CONTAINING GABAA
RECEPTOR AGONISTS**

(71) Applicants: **UWM Research Foundation, Inc.,
Milwaukee, WI (US); Centre for
Addiction and Mental Health, Toronto
(CA); University of Belgrade—Faculty
of Pharmacy, Belgrade (RS)**

(72) Inventors: **James M. Cook, Milwaukee, WI (US);
Guanguan Li, Milwaukee, WI (US);
Michael Ming-Jin Poe, Vernon, CT
(US); Miroslav M. Savić, Belgrade
(RS); Etienne Sibille, Toronto (CA)**

(73) Assignees: **UWM Research Foundation, Inc.,
Milwaukee, WI (US); Centre for
Addiction and Mental Health, Toronto
(CA); University of Belgrade—Faculty
of Pharmacy, Belgrade (RS)**

(56) **References Cited**
U.S. PATENT DOCUMENTS

4,226,768 A	10/1980	Walser
7,119,196 B2	10/2006	Cook et al.
7,235,656 B2	6/2007	Cook et al.
8,835,424 B2	9/2014	Cook et al.
9,006,233 B2	4/2015	Cook et al.
9,597,342 B2	3/2017	Cook et al.
10,259,815 B2	4/2019	Cook et al.
RE47,475 E	7/2019	Cook et al.
2003/0176456 A1	9/2003	June et al.
2004/0082573 A1	4/2004	Cook et al.
2006/0003995 A1	1/2006	Cook et al.
2006/0258643 A1	11/2006	Cook et al.
2009/0093466 A1	4/2009	Mattson
2009/0183566 A1	6/2009	Brown et al.
2010/0004226 A1	1/2010	Cook et al.
2010/0130479 A1	5/2010	Cook et al.
2010/0261711 A1	10/2010	Cook et al.
2010/0317619 A1	12/2010	Cook et al.
2012/0295892 A1	11/2012	Cook et al.
2015/0258128 A1	9/2015	Cook et al.

FOREIGN PATENT DOCUMENTS

GB 1527131 A 10/1978

- 3) **2023 - Početak komercijalizacije patenata: Patentna prava u oblasti razvoja lekova selektivnih za alfa5GABAA receptora za tretman kognitivnih deficita u različitim neuropsihijatrijskim stanjima otkupila spin-off kompanija sa sedištem u Kanadi Farmaceutski fakultet povratio sva prethodna ulaganja u prijavu i održavanja patenta US10906909 i stekao srazmerne tantijeme u budućim koracima razvoja leka-kandidata.**
- 4) **2024 - Pripreme za odobravanje prvog kliničkog ispitivanja leka-kandidata iz patenta US10906909.**